Home/Pipeline/Oncology Drug Delivery

Oncology Drug Delivery

Cancer (unspecified)

Pre-clinicalActive

Key Facts

Indication

Cancer (unspecified)

Phase

Pre-clinical

Status

Active

Company

Sporegen

About Sporegen

Sporegen is a pioneering private biotech firm specializing exclusively in Bacillus spore technology, positioning itself as a unique player in the global market. Its platform centers on developing heat-stable mucosal vaccines (SporeVax®), targeted drug delivery for oncology, and novel probiotic strains, aiming to address significant unmet needs in vaccine stability and targeted therapy. The company appears to be in a pre-clinical or early development stage, engaging in contract services to support its R&D while building a proprietary pipeline. Its strategic sponsorship of international conferences indicates an active effort to establish scientific credibility and partnerships within the field.

View full company profile

Therapeutic Areas

Infectious Disease Oncology

Other Cancer (unspecified) Drugs

Drug	Company	Phase	Status
CAR-engineered NK cells	Glycostem	Pre-clinical	Active
Lead Universal CAR-T Candidate	Allogenica	Pre-clinical	Active
ADU-1805	Sairopa	Preclinical	Active
PSC-derived NK Cells	HebeCell	Pre-clinical	Active
mRNA CAR-γδ-T Cell Platform	PhosphoGam	Pre-clinical	Active
R-5780	Rise Therapeutics	Phase 1	Active
Dendritic Cell-Based Cancer Vaccines	Celica Biomedical	Pre-clinical	Active
PD-1/VEGF Program	OncoC4	Not Disclosed	Active